Report #2888471

Received Mar 11, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: MA
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
HEP	HEP B (HEPLISAV-B)	DYNAVAX TECHNOLOGIES CORPORATION	1	943888	SYR

Symptoms (2)

Incorrect route of product administrationNo adverse event

Symptom narrative

Administered HEPLISAV-B IV Instead of IM; Initial report received on 13-Feb-2026. A pharmacist reported that a 75-year-old female received HEPLISAV-B (hepatitis B vaccine) for hepatitis B immunization intravenously instead of intramuscularly. No medical history or concomitant medications were reported. On an unknown date, the patient received dose 1 of a hepatitis B vaccine [HEPLISAV-B (lot number 943888, expiration date 14-May-2026; and NDC number 139527430013)] intravenously instead of intramuscularly. The patient was monitored for 45 minutes after the dose was given. The patient had no symptoms verbalized during or after administration. No other information was available. Company Comment: The company assessed the event as non-serious.; Sender's Comments: The company assessed the event as non-serious.